Naproxen

Jump to: navigation, search

Synonyms / Brand Names: Aleve, Anaprox, Bonyl, DL Naproxen, DL-Naproxen, Diocodal, Dysmenalgit, Ec-naprosyn, Equiproxen, Floginax, Laraflex, Laser, Mnpa, Naixan, Naprelan, Napren, Naprium, Naprius, Naprosine, Naprosyn, Naprosyne, Naproxen Sodium, Naprux, Naxen, Naxyn, Niaxan, Nycopren, Panoxen, Pranoxen, Prexan, Proxen, Proxine, Reuxen, Veradol, Xenar x

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Dosing and Administration

Geriatric Patients
Studies indicate that although total plasma concentration of Naproxen is unchanged, the unbound plasma fraction of Naproxen is increased in the elderly. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose.

Patients with Moderate to Severe Renal Impairment
Naproxen-containing products are not recommended for use in patients with moderate to severe and severe renal impairment (creatinine clearance < 30 mL/min).

Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis

  • 275 mg (Naproxen 250 mg with 25 mg sodium) twice daily
  • or 550 mg (Naproxen 500 mg with 50 mg sodium) twice daily


For more information on dosing please refer to Instructions for administration



FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.

Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.

Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.

Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information

Trial Resources
Ongoing Trials, Trial Results

Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.

Media Resources
Slides, Video, Images, MP3, Podcasts, etc.

Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.

International Resources
en Español






FDA Package Insert Resources

Indications

Contraindications

Side Effects

Drug Interactions

Precautions

Overdose

Instructions for Administration

How Supplied

Pharmacokinetics and Molecular Data

FDA label

FDA on Naproxen

Return to top

Publication Resources

Most Recent Articles on Naproxen

Review Articles on Naproxen

Articles on Naproxen in N Eng J Med, Lancet, BMJ

WikiDoc State of the Art Review

Textbook Information on Naproxen

Return to top

Trial Resources

Ongoing Trials with Naproxen at Clinical Trials.gov

Trial Results with Naproxen

Return to top

Guidelines & Evidence Based Medicine Resources

US National Guidelines Clearinghouse on Naproxen

Cochrane Collaboration on Naproxen

Cost Effectiveness of Naproxen

Return to top

Media Resources

Powerpoint Slides on Naproxen

Images of Naproxen

Podcasts & MP3s on Naproxen

Videos on Naproxen

Return to top

Patient Resources

Patient Resources on Naproxen

Discussion Groups on Naproxen

Patient Handouts on Naproxen

Blogs on Naproxen

Naproxen in the News

Naproxen in the Marketplace

Return to top

International Resources

Naproxen en Español

Return to top


The content of this page is taken from the FDA package insert for this drug and should not be edited.


Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg
Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox